Observational studyWorld journal of gastroenterology2024

Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease.

Jeremy Liu Chen Kiow et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.